Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04511026 · ClinicalTrials.gov registry record · Phase 2
Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04511026: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT04511026 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04511026, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The goal of this study is to (i) improve detection of sentinel nodes and (ii) reduce additional surgical dissection that is needed in case a sentinel lymph node cannot be detected.
Interventions
- DRUG Indocyanine Green (ICG)
- DRUG Lymphoseek
- DEVICE Single Photon Emission Computed Tomography (SPECT)
- DEVICE Neoprobe Gamma Detection System NPB11L(Model1102)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-01-20 |
| Est. Completion | 2021-06-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04511026
The ClinicalTrials.gov registry entry for NCT04511026 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Indocyanine Green (ICG) is the first listed.
NCT04511026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04511026 about?
NCT04511026 is a clinical study titled "Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer". The goal of this study is to (i) improve detection of sentinel nodes and (ii) reduce additional surgical dissection that is needed in case a sentinel lymph node cannot be detected.
What is the current status of trial NCT04511026?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2021-01-20. Estimated completion is 2021-06-10.
What interventions are being tested in trial NCT04511026?
The interventions under investigation include: Indocyanine Green (ICG) (DRUG), Lymphoseek (DRUG), Single Photon Emission Computed Tomography (SPECT) (DEVICE), Neoprobe Gamma Detection System NPB11L(Model1102) (DEVICE).
Who is sponsoring clinical trial NCT04511026?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.